Tetra Goes Buying, Volume Sings

By: Tomas Ronolski - AllPennyStocks.com News

Tuesday, November 6, 2018

Tetra Bio-Pharma Inc. (TSX-Venture:TBP) caused investors to sit up and take notice Tuesday morning, on word the company has found a partner for much of its stock.

The Ottawa-area firm – claiming to be “a leader in cannabinoid-based drug discovery and development”—has approached the shareholders of Panag Pharma Inc. to buy the latter’s issued and outstanding shares.

Panag is a Canadian-based life sciences company focused on the development of novel cannabinoid-based formulations for the treatment of pain and inflammation.

Tetra CEO Guy Chamberland said, “We have been working with Panag for over a year and as a combined entity we will have a robust product pipeline of cannabinoid derived drugs for development as prescription or OTC drugs.”

Chamberland continued, “Tetra is not just acquiring assets and intellectual property; we are joining a group of world-renowned cannabinoid experts that will help take Tetra to the next level as a pharmaceutical company.”

Panag will remain a separate subsidiary owned 100% by Tetra and will provide Tetra with additional discovery and early phase drug development capacity.

As for Tetra shares, they acquired a penny, or 1%, to $1.05, on a volume of 548,000

Copyright © 2018 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.